Al-Jameel, W, Gou, X, Jin, X, Zhang, J, Wei, Q, Ai, J, Li, H, Al-Bayati, A ORCID: 0000-0001-8223-6284, Platt-Higgins, A, Pettitt, A et al (show 2 more authors)
(2019)
Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ.
Genes and Cancer, 10 (3-4).
pp. 80-96.
This is the latest version of this item.
Text
192-Published-online.pdf - Published version Available under License : See the attached licence file. Download (7MB) | Preview |
|
Text
Waseem-2019-Genes+Cancer.pdf - Published version Available under License : See the attached licence file. Download (7MB) |
Abstract
Previous study has suggested that the FABP5-PPARγ-signalling transduction pathway gradually replaces the androgen receptor activated pathway in promoting malignant progression of castration-resistant prostate cancer (CRPC) cells. To interfere with this newly discovered FABP5-related signalling pathway, we have produced a highly efficient recombinant FABP5 inhibitor, named dmrFABP5. Treatment with dmrFABP5 significantly supressed the proliferation, migration, invasion and colony formation of the highly malignant prostate cancer cells PC3-M in vitro. To test dmrFABP5’s suppressive effect in CRPC, the human PC3-M cells were implanted orthotopically into the prostate gland of immunosuppressed mice to produce tumours. These mice were then treated with dmrFABP5 and produced a highly significant reduction of 100% in metastatic rate and a highly significant reduction of 13-fold in the average size of primary tumours. Immunocytochemial staining showed that the staining intensity of dmrFABP5 treated tumours was reduced by 67%. When tested in vitro, dmrFABP5 suppressed the cancer cells by blocking fatty acid stimulation of PPARγ, and thereby prevented it activating down-stream cancer-promoting or inhibiting cancer-suppressing genes. Our results show that the FABP5 inhibitor dmrFABP5 is a novel molecule for treatment of experimental CRPC and its inhibitory effect is much greater than that produced by SB-FI-26 reported in our previous work.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | CRPC, FABP5, PPARγ, dmrFABP5, tumorigenicity |
Depositing User: | Symplectic Admin |
Date Deposited: | 08 Aug 2019 09:39 |
Last Modified: | 19 Jan 2023 00:36 |
DOI: | 10.18632/genesandcancer.192 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3050267 |
Available Versions of this Item
-
Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. (deposited 04 Jun 2019 07:57)
- Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. (deposited 08 Aug 2019 09:39) [Currently Displayed]